


ЎЗБЕКИСТОН РЕСПУБЛИКАСИ СОҒЛИҚНИ САҚЛАШ ВАЗИРЛИГИ  
ТОШКЕНТ ТИББИЁТ АКАДЕМИЯСИ

2024

2011 йилдан чиқа бошлаган

TOSHKENT TIBBIYOT AKADEMIYASI  
**AХВОРОТНОМАСИ**



**ВЕСТНИК**

ТАШКЕНТСКОЙ МЕДИЦИНСКОЙ АКАДЕМИИ

SPECIAL EDITION

Only English "ADVANCES IN MEDICAL  
RESEARCH AND PRACTICE  
CONFERENCE"

Тошкент

prevalent among women than men. The lipid spectrum before the treatment with statin and ezetimibe were very high. Between the age of 17-39 The lipid spectrum before the drug was high LDL-C-120-180mg/dl,HDL30-48mg/dl,TG-180mg/dl,After the drug Ezetimibe its decreased gradually, LDL-100-110mg/dl,HDL-50-60mg/dl,TG-120mg/dl.Between the age 40-59 were with stage 3 with high BP and LDL-C-130-160mg/dl,HDL-50-60mg/dl,TG-200mg/dl,After the drug Atorvastatin the LDL-C is decreased by 90-120mg/dl,HDL-65-80mg/dl,TG-135mg/dl. Patients above the age of 60 were stage 2 mostly LDL-C is 140-160mg/dl,HDL-40-70mg/dl,TG-160mg/dl,After the drug statin the LDL-C is decreased by 120-90mg/dl,HDL-80-87mg/dl,TG-100mg/dl.A larger study evaluating dyslipidemia is >21000 incident lipid dialysis patients found 82%prevalance of dyslipidemia.overall,23.7% of the study sample had CKD n=580mean eGFR 50ml/min per 1.73 m<sup>2</sup> with stage 3 stage3 is associated with CVD (RR=1.17,95%CI 0.99-1.38,p=.006,upon testing CVD risk,the risk of CVD for Stage 3 among participants was significantly lower with prior CKD and no stage 3 ,CVD=0.66[95%CI 0.47 to 0.91],P=0.01.improved lipid profile (means difference:70mg/dl,95%CI,p<0.0001.

**Conclusion:** As an objective of the information which was mentioned above. The patients with CKD after their drug treatment the LDL-, HDL, TG levels were gradually decreased and shown good results which helps to manage the CKD patients in statin drug as compared to ezetimibe When it comes to managing cholesterol levels in chronic kidney disease (CKD), statins are generally considered more effective than ezetimibe. Statins, such as atorvastatin or simvastatin, are widely used to lower LDL cholesterol levels and have been shown to reduce cardiovascular risk, which is particularly important for CKD patients who are at higher risk of cardiovascular events.

#### DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF CLINICAL, LABORATORY AND IMMUNOLOGICAL INDICATORS IN KIDNEY DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS

Miraxmedova X.T. Aybergenova X.Sh.

*Tashkent Medical Academy, Tashkent, Uzbekistan*

Lupus nephritis (LN) is a common and serious disease of systemic lupus erythematosus (SLE) that causes long-term kidney damage and negatively affects patient survival.

The aim of the study: to investigate the diagnostic and prognostic value of clinical, laboratory, and immunological studies of lupus nephritis in systemic lupus erythematosus

**Materials and methods of the study:** The study was conducted in the department of rheumatology and nephrology of the multidisciplinary clinic of the Tashkent Medical Academy on 40 patients with SLE.

**Result:** proteinuria, hematuria, creatinine and urea were 56.7%, 36.7% and 23.3% in the SLE / without LN group. Of the general clinical laboratory tests in the SLE / without LN group, the average serum color index was  $0.87 \pm 0.03$ , and the average SLE / LN index was  $0.65 \pm 0.065$ . Of the biochemical laboratory tests, the average ferritin value in SLE / LN was  $19.98 \pm 0.05$  in the group, SLE / without LN -  $32.89 \pm 0.06$  in the group. According to the results of the general clinical laboratory tests, hemoglobin in SLE / without LN in the group of patients, hemoglobin averages  $99.5 \pm 1.44$  g / l; SLE/LN in the group of patients -  $80.23 \pm 1.05$  g/l; erythrocytes SLE/without LN in the group of patients -  $3.2 \pm 0.15$ ,  $2 \times 10^{12}/l$ ; SLE/LN in the group of patients -  $2.9 \pm 0.06 \times 10^{12}/L$  became. Leukocytes in the SLE/ no LL group was  $6.5 \pm 0.41$ ; while in the SLE/LL group was  $7.1 \pm 0.21 \times 10^9/L$ . It was noticed that ESR in the SLE/no LL group was  $17.3 \pm 1.1$  mm/s, and in the SLE/LL group  $20.1 \pm 1.48$  mm/s; Proteinuria in the SLE/no LL group was  $0.3 \pm 0.29$ ; SLE/LL was  $1.2 \pm 0.18$ , in the SLE/no LL group the specific urine total was  $1011.1 \pm 0.45$ ; and in the SLE/LL group a decrease of  $1009.4 \pm 0.41$  could be seen. From biochemical studies, total protein was  $65.3 \pm 1.09$  in the SLE/no LL group; in the SLE/LN group  $58.1 \pm 0.44$ . Of the parameters determining the morphofunctional state of the liver, ALT showed standard values of  $27.7 \pm 1.8$  in the SLE/without LN group; AST  $24.3 \pm 1.9$ ; bilirubin  $16.9 \pm 0.34$ ; and in patients in the SLE/LN group ALT  $25.5 \pm 0.916$ ; AST  $20.6 \pm 0.88$ ; bilirubin  $15.8 \pm 0.40$ . Potassium, representing mineral imbalance, occupied a relatively lower limit of the criterion of  $3.8 \pm 0.04$  in the group without systemic lupus erythematosus and  $3.7 \pm 0.08$   $\mu\text{mol/l}$  in patients in the group with systemic lupus erythematosus and nephritis. Glucose showed critical values in the SLE/no LD group  $4.97 \pm 0.08$ ; and in the SLE/LD group  $5.8 \pm 0.07$ . The indicator associated with hemostasis fibrinogen in both groups showed almost the same results by the criterion  $347 \pm 10.94$  and  $349.1 \pm 11.81$ , while thrombotest showed a slight increase with values  $5.27 \pm 0.074$  and  $5.29 \pm 0.077$ , indicating that the process of hypercoagulation in the glomeruli is still ongoing.

**Conclusion:** This means that as the disease progresses, there is a progression of kidney damage. But it would be worthwhile to check at what stage of the disease the kidney damage occurs, kidney biopsy, biomarkers, cytokines, which are the gold standard for our assessment of the effectiveness of treatment.

Содержание	
<b>I. SECTION. THERAPY3</b>	
<i>Abdullayeva M.I., Inoyatova F.Kh., Matchanov A., Ulugbek Zaribbayevich, Mirakhmedova K.G. PHARMACOLOGICAL CORRECTION OF FATTY LIVER DISEASE BY SUPRAMOLECULAR COMPLEXES OF GALLIC ACID</i>	4
<i>Nabieva D.A, Akramova N.T, Aditya Kush PATHOPHYSIOLOGICAL BASES OF THE RELATIONSHIP BETWEEN GOUT AND HAEMOSTASIS DISORDERS</i>	4
<i>Khakimov M.Sh., Ashurov Sh.E., Davlatov U.Kh. OPTIMIZATION OF DIAGNOSTIC AND TREATMENT TACTICS FOR BENIGN OBSTRUCTION OF THE EXTRAHEPATIC BILE DUCTS</i>	5
<i>Khakimov M.Sh., Ashurov Sh.E., Davlatov U.Kh. DEVELOPMENT AND OPTIMIZATION OF TREATMENT TACTICS FOR BLEEDING FROM THE PAPILOTOMY ZONE DURING RETROGRADE INTERVENTIONS</i>	6
<i>Botirova A.N THE INFLUENCE OF HYPERPARATHYROIDISM ON THE APPEARANCE OF PANCREATITIS</i>	6
<i>Saidrasulova G.B., Kalash D., Rahmonova U.T. CASE REPORT: DIFFUSE SYSTEMIC SCLEROSIS WITH ACUTE SUBACUTE ONSET COMPLICATED BY MULTI-ORGAN INVOLVEMENT, APPROACH TO TREATMENT AND MANAGEMENT</i>	7
<i>Toshmatova.M.B CHILDREN CEREBRAL PALSYPASTIC DIPLEGIA</i>	7
<i>Saidrasulova G.B., Janani Velu TREATMENT OPTIONS FOR DYSLIPIDEMIA IN CHRONIC KIDNEY DISEASES</i>	9
<i>Miraxmedova X.T. Aybergenova X.Sh. DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF CLINICAL, LABORATORY AND IMMUNOLOGICAL INDICATORS IN KIDNEY DAMAGE IN SYSTEMIC LUPUS ERYTHEMATOSUS</i>	10
<i>Akhmedova M.D. Imamova I.A., Karimova M.T., Mirzaeva G.A. EXPLORING THE IMMUNOLOGICAL INTERACTION OF ASCARIDA AND H. PYLORI</i>	11
<i>Gaibnazarov S.S., Sayfiddin Q.Sh. Hoji, Saparbayeva J.S., Magrupov T.M. DEVELOPMENT OF A NEURAL NETWORK COMPLEX FOR EARLY THERAPEUTIC DIAGNOSTICS OF LUNG DISEASES</i>	11
<i>Baltabaeva G.Sh. HYPERPROLACTINEMIA AND PREGNANCY</i>	12
<i>Ibragimova D.Y., Umarova F.N. CLINICAL AND ORGANIZATIONAL FEATURES AND DEVELOPMENT OF A SYSTEM FOR PROVIDING SPECIALIZED MEDICAL CARE TO PATIENTS WITH VIRAL PNEUMONIA CAUSED BY SARS-COV-2»</i>	13
<i>Ikramova S. "APPROACH TO ASSESSING THE RISK OF COMPLICATIONS FROM CORONAVIRUS INFECTION IN PATIENTS WITH EPILEPSY"</i>	13
<i>Makhkamova M.M., Nurillayeva N.M. PREVALENCE OF METABOLIC DYSFUNCTION IN POSTMENOPAUSAL WOMEN DIAGNOSED WITH CORONARY ARTERY DISEASE</i>	14
<i>Bobonazarova M. N, Matkarimova D. S. RESISTANCE TO TYROSINE KINASE INHIBITORS IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA</i>	14
<i>Mamadjanova Kh.Kh. RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS WITH TYPE 2 DIABETES</i>	15
<i>Mamadjanova Kh.Kh., Mirzayeva Kh.A. CLINICAL MANIFESTATIONS OF OSTEOPAROSIS IN PATIENTS WITH TYPE 2 DIABETUS MELLITUS</i>	15
<i>Mirzamarova F.T., Ibdullaeva M.A., R. Q. Karakhanov. VARIOUS HEMODYNAMICS OF CHRONIC H EART FAILURE ROLE OF ALDOSTERONE IN ASSESSMENT OF FIBROSIS PROCESSES</i>	16
<i>Saddam Shaikh. NOVEL AND EMERGING THERAPIES FOR INFLAMMATORY BOWEL DISEASE (IBD)</i>	16
<i>Nuriddinova N.F., Kurbonova Z.Ch., Zaynutdinova D.L. IMPORTANCE OF ENDOTHELIAL MARKERS IN PATIENTS WITH CHRONIC HEPATITIS C AND LIVER CIRRHOSIS.</i>	18
<i>Muxamediyeva I.B. THE EFFECT OF ISOQUINOLINE ALKALOIDS F-4 AND F-24 ON THE DYSFUNCTION OF RAT HEART MITOCHONDRIA UNDER CONDITIONS OF OXIDATIVE STRESS</i>	18
<i>Riddhi Shailendra Mishra, M.Sh.Abdujalilova. PSYCHOEMOTIONAL BACKGROUND IN CHILDREN WITH BRONCHIAL ASTHMA</i>	19
<i>Gafurova D.S., Inoyatova F.X. THE EFFECT OF NON-ALCOHOLIC FATTY LIVER DISEASE ON THYROID FUNCTION</i>	20
<i>Mirakhmedova Kh.T., Nizametdinova U.J. Saidrasulova G.B. THE EFFECT OF HYPERURICEMIA IN PATIENTS WITH OSTEOARTHRITIS AND METABOLIC SYNDROME.</i>	20
<i>Jumanazarova A.J. OBESITY - THE BASIS OF METABOLIC SYNDROME</i>	21
<i>Najmutdinova D.K., Sadikova A.S. MODERN METHODS OF TREATING OBESITY</i>	21
<i>Abdullayev R. B., Bakhtiyarova A. M. THERAPEUTIC AND DIETIC NUTRITION MANAGEMENT FOR ULCER DISEASE IN THE KHOREZM REGION</i>	22
<i>Matkarimov O.I., Akhmedova S.M. , Niyozov N.Q. MYOCARDIAL MORPHOLOGY ON THE BACKGROUND OF DIABETES</i>	23